glp-1 agonists - Page 1 | CARLAT PUBLISHING

Research Update

Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder

November 1, 2025

Anna Vinter, MD. Dr. Vinter has no financial relationships with companies related to this material.

Alcohol use disorder (AUD) is notoriously difficult to treat, with pharmacological options often underutilized or only modestly effective. But what if a medication already used for diabetes and obesity could help?

Liraglutide: A Generic Option for Weight Gain

June 1, 2025

Edmund S. Higgins, MD

Edmund S. Higgins, MD. Affiliate Associate Professor, Psychiatry and Behavioral Sciences, Medical University of South Carolina.

Dr. Higgins reports stock ownership in Bristol-Myers-Squibb and Johnson & Johnson. Dr. Aiken has reviewed this educational activity and determined that there is no commercial bias as a result of this financial relationship.

Liraglutide offers an affordable GLP-1 option for managing antipsychotic weight gain.

GLP-1 Receptor Agonists in Addiction Treatment: The Next Big Thing or Just Hype?

April 1, 2025

Michael Weaver, MD, FASAM and Noah Capurso, MD, MHS

Michael Weaver, MD, DFASAM. Professor and Medical Director, Center for Neurobehavioral Research on Addiction at the University of Texas Medical School, Houston, TX.

Noah Capurso, MD, MHS. Assistant Medical Director, Addiction Services Division, Connecticut Valley Hospital; Associate Clinical Professor of Psychiatry, Yale University; Editor-in-Chief, The Carlat Addiction Treatment Report.

Drs. Weaver and Capurso have no financial relationships with companies related to this material.

GLP-1 agonists have taken the world by storm, especially for weight loss—but emerging evidence suggests they may also play a role in addiction treatment. In this article, we review the latest research to highlight when these medications might offer the greatest benefit for patients with substance use disorders.